# A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

> **NCT06868199** · PHASE1,PHASE2 · RECRUITING · sponsor: **LaNova Medicines Limited** · enrollment: 87 (estimated)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** LM-168
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06868199
- **Lead sponsor:** LaNova Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868199, "A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06868199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*